Bacteriological Profile and Antibiotic Resistance Pattern at the Yaounde University Teaching Hospital: A Retrospective Study

Daniele Sandra Yopa1*, Hortense Gonsu Kamga2, Emmanuel Nnanga Ngaa3, Olive Nathalie Kouamen Njikeu2, Claude Stephan Ohandza4, and Georges Nguefack-Tsague1

1Department of Public Health, University of Yaounde 1, Yaounde, Cameroon.
2Department of Microbiology-Parasitology-Hematology, University of Yaounde 1, Yaounde, Cameroon.
3Department of Pharmacology, University of Yaounde 1, Yaounde, Cameroon.
4Department of Infectious and Tropical Diseases, Fann University Teaching Hospital, Dakar, Senegal.

Authors’ contributions

This work was carried out in collaboration among all authors. Authors DSY, HGK, ENN, GNT designed the study, performed the statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. Authors ONKN and CSO managed the analyses of the study and the literature searche. All authors read and approved the final manuscript.

ABSTRACT

Aims: Over the decades, antibiotic resistance has become a cross-border public health problem. This calls for the profiling of microorganisms, particularly bacteria implicated in antibiotic resistance, in order to improve clinical practice and reduce the incidence of therapeutic failure in the treatment of infectious diseases.

Study Design: We conducted a retrospective cross-sectional study.

Place and Duration of the Study: The study was made at the bacteriology laboratory at the Yaounde University Teaching Hospital, Cameroon during the period between January 2016 and June 2021.
**Methodology:** All bacterial strains from the following biological fluids were included: blood, stool, urine, suppurations, probe tip and catheter tip. The antibiotic susceptibility of isolates was collected from the registers of the said laboratory. The data were encoded in Censuses and Survey Procession Software (CSPro) version 7.3 and analysed using the Statistical Package for Social Science (SPSS) version 25. Graphs and figures were made using Excel 2016 spreadsheet software.

**Results:** A total of 1071 bacteria were enrolled in 955 patients. The age group most represented was 0-5 years (34.6%). Most of the isolates came from a blood sample. Among the isolates, *Coagulase-negative Staphylococci* (18.5%), *Escherichia coli* (17.7%), *Staphylococcus aureus* (14%) and *Klebsiella pneumoniae* (11.2%) were the most common. A total of 1071 bacteria were enrolled in 955 patients. The age group most represented was 0-5 years (34.6%). Most of the isolates came from a blood sample. Among the isolates, *Coagulase-negative Staphylococci* (18.5%), *Escherichia coli* (17.7%), *Staphylococcus aureus* (14%) and *Klebsiella pneumoniae* (11.2%) were the most represented. Between 2016 and 2020, almost remarkable resistance was observed to the class of penicillins (78% to 83%), cephalosporins (44% to 61%) and quinolones (43% to 100%) for *Escherichia coli*. For *Staphylococcus aureus*, resistance changes range from 68% to 77% for the penicillin class. *Klebsiella pneumoniae* showed an evolution ranging from 11% to 19% for aminosides.

**Conclusion:** Although not all isolates showed a change in the level of resistance to all antibiotics that are frequently used in our study population. Nevertheless, it is important for national public health actors to establish active surveillance of antibiotic and even antimicrobial resistance and to implement a guide to the proper use of antibiotics for health professionals, and the community.

**Keywords:** Antibiotic resistance pattern; bacteriological profile; Yaounde; laboratory.

1. **INTRODUCTION**

Antibiotics have long helped in the management of infectious diseases and in reducing the risk of infection in various clinical scenarios such as for immunocompromised, chemotherapy and surgical patients [1]. However, it’s resistance has become a global public health crisis over the decades with the spread of multi-resistant bacteria [2]. Whether natural, acquired, cross-resistance or co-resistance, the disaster of increasing antibiotic ineffectiveness is now an established reality in every country in the world [2–6].

Beyond the innate trait of resistance of bacteria to certain antibiotics, the development of acquired resistance through overuse of antibiotics is also incriminated [7]. The lack of improvement in the general condition of patients after mono- or dual-antibiotic therapy hinders medical practice. More and more clinicians are faced with therapeutic impasses making the management of infectious diseases more complex [2,4,8,9]. Prolonged costs of care are a source of financial decline in households and society (4). A study conducted in 17 European countries found that fee-for-service payment for physicians was associated with higher antibiotic use [10].

According to the World Health Organisation (WHO), more than 700,000 deaths per year are somehow attributed to antimicrobial resistance, which is expected to claim 10 million lives and cost $100 trillion by 2050 [3,10–12]. It ranks antibiotic resistance as a global security threat on a par with terrorism and climate change [10]. In order to control the rapid rise of this threat, it has proposed the establishment of a Global Antimicrobial Resistance Surveillance System (GLASS) whose readiness is regularly assessed and whose priority pathogens for surveillance are: *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumanii*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Salmonella spp*, *Shigella spp* and *Neisseria gonorrhoeae* [13–16].

Rates of faecal colonisation by betalactamase-producing Enterobacteriaceae are estimated at 14% in healthy individuals worldwide, with an annual increase of about 5% between 1990 and 2015. These rates are highest in the Mediterranean, Western Pacific, Africa and South-East Asia, and lowest in Northern Europe and North America [17]. In 2016, a meta-analysis found that only 42.6% of countries on the African continent had data on antimicrobial resistance (AMR). Penicillin resistance in *Streptococcus pneumoniae* was reported in 14/144 studies, median resistance (MR: 26.7%). In addition,
18/53 (34.0%) of Haemophilus influenza isolates were resistant to amoxicillin. Multidrug resistance of *Escherichia coli* to amoxicillin, trimethoprim and gentamicin was 88.1%, 80.7% and 29.8% respectively. In contrast, resistance to ciprofloxacin in *Salmonella typhi* was rare [3].

Low-income countries are most affected by antimicrobial resistance related infections, such as community-acquired infections [9,18–22]. A study by Lonchel and al in Yaounde on 358 faecal samples, showed *Escherichia coli* as the most frequently isolated ESBL producer in ambulatory patients (66.7%) and student volunteers (90%). Isolates showed additional resistance to gentamicin, ciprofloxacin and trimethoprim/sulfamethoxazole [23]. Studies conducted at the Douala General Hospital in Cameroon reported high resistance of *Escherichia coli* and *Klebsiella* spp to third-generation cephalosporins, penicillins and cotrimoxazole, as well as *Staphylococcus aureus and coagulase-negative staphylococci* showing more than 50% resistance to meticillin, respectively [24,25]. In 2016, hospitals in Cameroon reported a total of 25,975 cases of tuberculosis, including 175 (0.7%) cases of multidrug resistance [26].

In view of the challenge posed by this scourge to date, and the ever-increasing prevalence of AMR, we proposed to take stock of the situation based on recent epidemiological data on antimicrobial resistance. In the framework of our study, we will evaluate the antimicrobial resistance profile in the laboratory of the University Teaching Hospital in Cameroon over a period of 04 years and 06 months. More precisely, we will proceed with a census of the bacteria isolated in the Yaounde University Teaching Hospital (YUTH) laboratory during the study period. Then we will establish the antibiotic resistance profile by year and finally we will show the evolution of the resistance profile of the main strains found by year.

2. METHODOLOGY

2.1 Design

We have conducted a retrospective study with a descriptive aim. Our study has taken place over a total period of 04 years and 06 months from January 2016 to June 2021. Our study has been conducted at the Yaounde University Teaching Hospital (YUTH) in Cameroon. The YUTH was created in 1978 in order to offer students of the Faculty of Medicine and Biomedical Sciences a better practical and adapted training. It is both a teaching hospital guaranteeing rigorous care and quality training for future health professionals, and a sentinel site for the emerging antimicrobial surveillance in Cameroon. Our source population consisted of bacterial strains considered to be resistant bacteria and which have been isolated from diagnostic samples taken from people of all ages and sexes. All bacterial strains from the following biological fluids were included: blood, stool, urine, suppurations, probe tip and catheter tip. We have carried out exhaustive sampling during the entire recruitment period.

2.2 Procedure

2.2.1 Search of archives and registers

After obtaining the agreement of the Director of the YUTH, we collected the data based on the archived records, we selected the results that met the inclusion criteria at the bacteriology laboratory of the YUTH Hospital.

2.2.2 Selection of results

A pre-established and pre-tested data collection form was conceived. The information collected were place of hospitalisation, age, sex, nature of the bacteria, date of isolation, sampling site, department concerned, antibiotic sensitivity profile tested for each antibiotic, percentage of resistance in each species.

2.3 Research for Resistant Bacteria

This part of the procedure is intended as an indication of the technique used in the laboratory to obtain the results.

2.3.1 Sampling

Biological products were collected from the various departments of the YUTH. After the preliminary verifications in the laboratory, the macroscopic analysis of the samples was performed. This was followed by the culture phase, which depended on the biological fluid taken. Different specific culture media were used [27,28].

2.3.2 Morphological characteristics

2.3.2.1 Fresh state

A drop of bacterial suspension was observed under a light microscope with a 10X and then
40X objective. This was done to determine the shape, arrangement and especially the mobility of the bacteria.

2.3.2.2 Quantitative cytology

Urine cytology was used with the Kova cell. This analysis consisted of counting the number of red blood cells and white blood cells in a given volume of pathological products [28].

2.3.3 Gram staining

Gram staining was performed to identify bacterial morphologies. This stain classifies bacteria according to their ability to bind crystal violet. After staining, we observed the bacteria under a microscope at high magnification (under a 100X objective). We could have: Gram-positive bacilli, Gram-negative bacilli, Gram-positive cocci, Gram-negative cocci and Yeast [28].

2.3.4 Identification and typing of bacteria

After the Gram staining, we made an inoculum which we enmeshed in an API gallery. API 20NE galleries were used for non-fermentative bacteria and API 20E galleries for fermentative bacteria. Based on the biochemical factors found in the gallery we were able to make a 90% identification of the genus and species [28].

2.3.5 Antibiotic susceptibility

The disk diffusion method used for the antimicrobial susceptibility testing (AST) was Kirby Bauer, according to the Antibiogram Committee of the French Microbiology Society. The medium used for the majority of bacterial species is Mueller-Hinton. The cell suspension was prepared in sterile physiological water from a young and pure culture on appropriate isolation medium with a suspension calibrated to 0.5 Mac Farland [27].

2.3.6 Plating of the antibiogram

This should be done 15 minutes after preparation of the inoculum. It is done by swabbing so that after incubation we obtain distinct but joined colonies. The swab was dipped into the suspension and the excess liquid was removed by turning the swab on the walls of the tube. To ensure good uniformity, we rubbed the entire surface of the agar dish three times, rotating the dish about 60°C between the streaks.

2.3.7 Application of the discs

The discs were applied manually with light pressure on the agar surface with sterile forceps to ensure complete contact of the disc with the agar, respecting the recommended distances between the discs [27].

2.3.8 Incubation of the antibiogram

The plates were then turned upside down and incubated ideally within 15 min of disc deposition, but not exceeding 30 min.

2.3.9 Reading of the antibiogram

After 16-18 hours of incubation, each plate was examined. The diameters of the resulting zones of inhibition were measured according to the Antibiogram Committee of the French Microbiology Society protocol.

2.4 Ethical Considerations

Before starting our research, a clearance from the Institutional Research Ethics Committee (IREC) of the Faculty of Medicine and Biomedical Sciences has been obtained and a research authorization from the Director of the Yaounde University Teaching Hospital has been obtained.

2.5 Data Analysis

All data collection forms were stored in a database designed under the Censuses and Survey Procession software (CSPro) version 7.3. The data were then analysed using Statistical Package for Social Science (SPSS) version 25.0. Graphs were done in Excel 2016. The categorical variables were presented in frequency and percentage. The antibacterial resistance rate was calculated by taking the number of times the study strain was resistant, divided by the number of times the strain was resistant and susceptible. The intermediate level of resistance was not considered for the calculation.

3. RESULTS

3.1 Sociodemographic and Bacteriologic Profile

During our study period, 1071 strains were isolated from 955 individuals during the period from January 2016 to June 2021. The sex ratio
M:F was 1:1 with 502 (52.6%) male and 453 (47.4%). The most represented referral service was the Paediatric Department followed by the Emergency Department as shown in the Fig. 2. The most represented age groups were 0-5 years and 60-65 years, respectively 34.6% and 5.8% (Table 1).

The strains isolated were mainly from blood cultures 578 (54%) and pus 221 (20.6%) as described in Table 2. Coagulase-negative staphylococci (CNS) were represented at 18.5% followed by Escherichia Coli (17.7%), Staphylococcus Aureus (14%) and Klebsiella Pneumoniae (11.2%).
Fig. 3. Frequency of isolation according to services

*** Other includes those services: ENT, Operating Theatre, Odontostomatology, Physiotherapy

Table 1. Bacteria found of our study population

| BACTERIA                                      | Number (strains) | Percentage (%) |
|-----------------------------------------------|------------------|----------------|
| Acinetobacter spp                            | 34               | 3.2%           |
| Citrobacter                                  | 18               | 1.7%           |
| Escherichia coli                             | 190              | 17.7%          |
| Enterobacter                                 | 29               | 2.7%           |
| Enterococcus spp                             | 25               | 2.3%           |
| Klebsiella                                   |                  |                |
| Klebsiella oxytyca                           | 13               | 1.2%           |
| Klebsiella ozaenae                           | 27               | 2.5%           |
| Klebsiella pneumoniae                        | 120              | 11.2%          |
| Klebsiella rhinoscleromaticis                | 20               | 1.9%           |
| Other Klebsiella                             | 5                | 0.5%           |
| Proteus                                      |                  |                |
| Proteus mirabilis                            | 13               | 1.2%           |
| Proteus vulgaris                             | 6                | 0.6%           |
| Other Proteus                                | 4                | 0.4%           |
| Pseudomonas                                  |                  |                |
| Pseudomonas aeruginosa                       | 12               | 1.1%           |
| Pseudomonas cepacia                          | 7                | 0.7%           |
| Pseudomonas of the fluorescens group         | 23               | 2.1%           |
| Other Pseudomonas                            | 6                | 0.6%           |
| Staphylococci                                |                  |                |
| Staphylococcus aureus                        | 150              | 14.0%          |
| Staphylococcus epidermitis                   | 44               | 4.1%           |
| Staphylococcus saprophiticus                 | 15               | 1.4%           |
| Coagulase negative staphylococci             | 198              | 18.5%          |
| Other staphylococci                          | 2                | 0.2%           |
| Streptococci                                 |                  |                |
| Streptococcus milleri                        | 7                | 0.7%           |
| Streptococcus sanguis                        | 4                | 0.4%           |
| Other streptococcus (non identified)         | 18               | 1.7%           |
| Other bacterial strains                      |                  |                |
| Providencia spp                              | 4                | 0.4%           |
3.2 Evolution of Bacterial Resistance of the Main Germs Found (2016-2020)

The report on the evolution of antibiotic resistance shows that in 2016 *Escherichia coli* strains were 78% resistant to penicillins, 44% to cephalosporins, 43% to quinolones and 6% to aminoglycosides. By the year 2020, the resistance of *Escherichia Coli* strains to penicillins has increased from 78% to 83%. Resistance to cephalosporins has increased from 44% to 61% and resistance to aminoglycosides has increased from 6% to 25%.

The report on the evolution of antibiotic resistance shows that in 2016, 68% of *Staphylococcus aureus* strains were resistant to penicillins, 67% to cephalosporins, 31% to quinolones, 20% to aminoglycosides, 36% to macrolides and 42% to tetracyclines. By the year 2020, the resistance of *Staphylococcus aureus* strains to penicillins has increased from 68% to 77%. Resistance to cephalosporins increased from 44% to 61%, resistance to aminoglycosides decreased from 20% to 11% and resistance to tetracyclines decreased from 42% to 30%.

*Klebsiella Pneumoniae* accounted for 72% of the *Klesiella* found. Some species were not specified (26.2%). Other species such as *Klebsiella Ozaenae* (1.8%) were poorly recorded. The report on the evolution of antibiotic resistance shows that in 2016, 97% of *Klebsiella Pneumoniae* strains were resistant to penicillins, 63% to cephalosporins, 36% to quinolones and 11% to aminoglycosides. Resistance to penicillins increased from 97% to 85%, to cephalosporins from 63% to 54%, to aminoglycosides from 11% to 19% and to quinolones from 36% to 17%.

3.3 Trends of Antibiotic Resistance

We note that all the mains bacteria studied that are: *E. coli*, *Staphylococci aureus* and *Klebsiella pneumonia*, show a resistance varying between 50% and 100% in general for the penicillin group as shown in the Fig. 3.

In the same line, all the mains bacteria studied, show a resistance varying between 30% and 100% in general for the cephalosporin (Fig. 5).

Also we observed that, all the mains bacteria studied, show a resistance varying between 10% and 100% in general for the quinolone (fig. 6).

4. DISCUSSIONS

Antimicrobial resistance has progressively become a public health problem of global concern. Increasing antibiotic resistance to certain pathogens will make it difficult to control and treat infectious diseases [29].

Men (53%) outnumbered women (47%) in this study. Although the margin is not significant, it is different from a study by Metchim and Madouni where women (61%) outnumbered men (39%). This could be explained by the difference in sample size between this 955 study and their 141 study [30].

The most isolated collection sites were blood (49%) and pus (25%) respectively. However, the other sites were urine (14%) and catheter tips (12%). This result is different from that of Alemayehu and Saravanan where the most represented sites of collection were urine, pus and blood. This could be explained by the difference in sample size, where our study counted 955 versus 693 [31]. Most of the samples were isolated in the age group 0-5 years, which is similar to Alemayehu and al.

*Coagulase-negative staphylococcus* (CoNS) was the most common bacterium, followed by *E. coli* in this study. This could be explained by the fact that the majority of the samples in this study were from the paediatric unit. *Coagulase-negative staphylococcus* and *E. coli*, among others, have been identified as major bacteria in neonatal sepsis [32].
Table 2. Evolution of *Escherichia Coli* resistance

|                | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|
| **Penicillins** |      |      |      |      |      |
| Amoxicillin    | 78%  | 83%  | 92%  | 76%  | 83%  |
| Amoxicillin+Clavulanic acid | 82%  | 90%  | 77%  | 81%  | 80%  |
| **Amoxicillin** | 75%  | 96%  | 86%  | 83%  | 100% |
| **Piperacillin** | 67%  | 79%  | 100% | 73%  | 71%  |
| **Ticarcillin** | 67%  | 67%  | 95%  | 0%   | 88%  |
| **Piperacillin+tazobactam** | -    | 11%  | 100% | 0%   | 0%   |
| **Ticarcillin+tazobactam** | -    | 100% | 100% | 50%  | 0%   |
| Ticarcillin+Clavulanic acid | -    | 100% | 100% | 78%  | 88%  |
| Amoxicillin     | -    | 0%   | 100% | 0%   | 100% |
| Oxacillin       | -    | -    | -    | -    | 100% |
| **Cephalosporins** |      |      |      |      |      |
| Cefalotin       | 44%  | 52%  | 66%  | 30%  | 61%  |
| Cefepime        | 64%  | 81%  | 89%  | 63%  | 80%  |
| Cefixime        | 75%  | 58%  | 100% | 23%  | -    |
| Cefotaxime      | 50%  | 75%  | 80%  | -    | -    |
| Cefoxitin       | 45%  | 11%  | 100% | 100% | 100% |
| Ceftazidime     | 33%  | 30%  | 40%  | 17%  | 0%   |
| Ceftaziidime    | 28%  | 29%  | 63%  | 39%  | 67%  |
| Ceftriaxone     | 55%  | 100% | 79%  | 5%   | 67%  |
| Cefuroxime      | 33%  | 50%  | 58%  | 40%  | 80%  |
| Ceftodoxime     | -    | -    | 100% | -    | -    |
| **Quinolones**  | 43%  | 50%  | 58%  | 12%  | 100% |
| Ciprofloxacin   | 29%  | 54%  | 56%  | 17%  | 100% |
| Levofloxacine   | 36%  | 55%  | 25%  | 0%   | -    |
| Norfloxacin     | 54%  | 22%  | 65%  | 0%   | -    |
| Ofloxacin       | 44%  | 50%  | 61%  | 0%   | 100% |
| Pefloxacin      | -    | -    | -    | 43%  | -    |
| Aminosides      | 6%   | 20%  | 8%   | 15%  | 25%  |
| Amikacin        | 0%   | 5%   | 0%   | 13%  | 13%  |
| Gentamycin      | 9%   | 32%  | 18%  | 29%  | 50%  |
| Netilmicin      | 0%   | 75%  | 33%  | 13%  | -    |
| Tobramycin      | 9%   | 10%  | 0%   | 0%   | -    |
| Carbapenemes    | 0%   | 6%   | 11%  | 9%   | 0%   |
| Imipenem        | 0%   | 0%   | 4%   | 0%   | 0%   |
| Ertapenem       | 0%   | 0%   | 33%  | 0%   | 0%   |
| Meropenem       | -    | 50%  | 16%  | 22%  | 0%   |
| **Other**       |      |      |      |      |      |
| Nalixidic acid  | 50%  | 73%  | 71%  | 65%  | 100% |
| Colistin        | 0%   | 71%  | 100% | 21%  | 100% |
| Cotrimoxazole   | 92%  | 71%  | 81%  | 20%  | 40%  |
| Fosfomycin      | 0%   | 8%   | 6%   | 17%  | 0%   |
| Nitrofurantoin  | 20%  | 72%  | 0%   | 3%   | 0%   |
| **TOTAL (strains)** | **24** | **43** | **43** | **54** | **14** |
|                      | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------------|------|------|------|------|------|
| **Penicillins**      | 68%  | 57%  | 72%  | 52%  | 77%  |
| Amoxicillin+clavulanic acid | 65%  | 27%  | 66%  | 48%  | 100% |
| Amoxicillin          | 100% | 100% | 94%  | 73%  | 100% |
| Ampicillin           | -    | -    | 10%  | -    | -    |
| Oxacillin            | 64%  | 80%  | 50%  | 21%  | 55%  |
| Piperacillin         | -    | -    | -    | -    | 100% |
| Penicillin G         | -    | -    | -    | 100% | -    |
| Ticarcillin+Clavulanic acid | -    | -    | -    | -    | 100% |
| Cephalosporins       | 67%  | 100% | 62%  | 60%  | 43%  |
| Cefalotin            | 100% | -    | 0%   | -    | -    |
| Cefixime             | 100% | -    | -    | -    | -    |
| Cefuroxime           | 100% | -    | 60%  | 47%  | -    |
| Cefotaxime           | 0%   | -    | -    | -    | -    |
| Ceftazidime          | -    | -    | 0%   | 100% | 100% |
| Ceftriaxone          | -    | -    | 100% | 0%   | -    |
| Cefoxitin            | -    | 100% | 68%  | 67%  | 42%  |
| Quinolones           | 31%  | 40%  | 57%  | 60%  | 31%  |
| Ciprofloxacin        | 0%   | -    | -    | 67%  | 38%  |
| Ofloxacin            | 100% | 25%  | 44%  | 50%  | 14%  |
| Levofloxacin         | 0%   | 100% | 100% | 60%  | 100% |
| Norfloxacin          | 0%   | -    | 100% | -    | -    |
| Aminosides           | 20%  | 54%  | 46%  | 40%  | 11%  |
| Tobramycin           | 8%   | 53%  | 57%  | 43%  | 20%  |
| Gentamycin           | 43%  | 57%  | 30%  | 38%  | 0%   |
| Netilmicin           | -    | -    | 100% | -    | -    |
| Kanamycin            | -    | -    | -    | 0%   | -    |
| Macrolides           | 36%  | 32%  | 28%  | 43%  | 28%  |
| Erythromycin         | 0%   | 0%   | 44%  | 47%  | 23%  |
| Clindamycin          | 45%  | 53%  | 14%  | 36%  | 40%  |
| Tetracycline         | 42%  | 65%  | 58%  | 60%  | 30%  |
| Tetracycline         | 73%  | 77%  | 56%  | 58%  | 50%  |
| Minocycline          | 15%  | 50%  | 59%  | 22%  | 0%   |
| Carbapenemes         | 0%   | -    | -    | 100% | 100% |
| Ertapenem            | -    | -    | -    | -    | 100% |
| Imipenem             | 0%   | -    | -    | 100% | -    |
| Meropenem            | -    | -    | -    | -    | 100% |
| **Other**            |      |      |      |      |      |
| Fusidic acid         | 45%  | 11%  | 11%  | 17%  | 17%  |
| Vancomycin           | 31%  | 29%  | 32%  | 3%   | 100% |
| Pristinamycin        | 50%  | 50%  | 23%  | -    | 0%   |
| Lincomycin           | 25%  | 0%   | -    | 0%   | 18%  |
| Cotrimoxazole        | 43%  | 30%  | 50%  | 50%  | -    |
| Rifamycin            | 0%   | 25%  | 8%   | 15%  | 22%  |
| **TOTAL (strains)**  | 19   | 20   | 45   | 44   | 15   |
Table 4. Evolution of *Klebsiella pneumonia* resistance

|                  | 2016 | 2017 | 2018 | 2019 | 2020 |
|------------------|------|------|------|------|------|
| Penicillins      | 97%  | 91%  | 90%  | 92%  | 85%  |
| Amoxicillin+clavulanic acid | 100% | 100% | 90%  | 85%  | 67%  |
| Amoxicillin      | 92%  | 100% | 100% | 100% | 100% |
| Ampicillin       | -    | -    | -    | -    | 100% |
| Piperacillin     | 100% | 88%  | 73%  | 87%  | 80%  |
| Piperacillin+tazobactam | -   | 0%   | 80%  | 100% | -    |
| Ticarcillin      | 100% | 100% | 94%  | 100% | 88%  |
| Ticarcillin-clavulanic acid | -   | 100% | 90%  | 100% | 100% |
| Ticarcillin+tazobactam | -   | 100% | 100% | 50%  | -    |
| Cephalosporins   | 63%  | 83%  | 76%  | 77%  | 54%  |
| Cefalotin        | 71%  | 92%  | 83%  | 77%  | 50%  |
| Cefepime         | 80%  | 75%  | 100% | 83%  | -    |
| Cefixime         | 25%  | 75%  | 50%  | -    | -    |
| Cefotaxime       | 63%  | 100% | -    | 100% | 60%  |
| Cefoxitin        | 50%  | 20%  | 54%  | 40%  | 50%  |
| Ceftazidime      | 67%  | 100% | 73%  | 90%  | 50%  |
| Ceftriaxone      | 100% | 100% | 93%  | 85%  | 50%  |
| Cefuroxime       | 53%  | 100% | 73%  | 75%  | 60%  |
| Quinolones       | 36%  | 61%  | 66%  | 72%  | 17%  |
| Ciprofloxacin    | 27%  | 64%  | 55%  | 54%  | 14%  |
| Pefoxacin        | -    | -    | 89%  | -    | -    |
| Levofloxacin     | 33%  | 33%  | 100% | 75%  | -    |
| Norfloxacin      | 47%  | 100% | 79%  | 82%  | 0%   |
| Ofloxacin        | 33%  | 55%  | 67%  | 67%  | 33%  |
| Aminosides       | 11%  | 41%  | 11%  | 37%  | 19%  |
| Amikacin         | 0%   | 25%  | 10%  | 20%  | 11%  |
| Gentamycin       | 22%  | 20%  | 13%  | 45%  | 0%   |
| Netilmicin       | 13%  | -    | -    | 75%  | 33%  |
| Tobramycin       | 100% | 100% | -    | -    | 100% |
| Tetracyclines    | 36%  | -    | 100% | -    | -    |
| Minocycline      | 0%   | -    | -    | -    | -    |
| Tetracycline     | 50%  | -    | 100% | -    | -    |
| **Other**        |      |      |      |      |      |
| Nalixidic acid   | 38%  | 62%  | 55%  | 50%  | 38%  |
| Fusidic acid     | 0%   | -    | -    | -    | -    |
| Aztreonam        | 50%  | 100% | 69%  | 81%  | 50%  |
| Chloramphenicol  | 100% | 50%  | -    | -    | -    |
| Colistin         | 100% | 80%  | 100% | 41%  | 33%  |
| Cotrimoxazole    | 91%  | 50%  | 100% | 92%  | 100% |
| Fosfomycin       | 0%   | 0%   | 58%  | 60%  | 60%  |
| Nitrofurantoin   | 27%  | 75%  | 16%  | 38%  | 50%  |
| Rifamycin        | -    | -    | -    | -    | -    |
| Vancomycin       | 50%  | -    | -    | -    | 100% |
| Teicoplanin      | -    | -    | -    | -    | 100% |
| **TOTAL (strains)** | **28** | **16** | **32** | **30** | **10** |
Fig. 4. Evolution of penicillin resistance

Fig. 5. Evolution of cephalosporin resistance (excluding nalixidic acid)

Fig. 6. Evolution of quinolone resistance

Resistance of *Staphylococcus aureus* to aminopenicillins, cephalosporins and aminoglycosides was identified in this study at 77%, 43% and 11% respectively in 2020. These results are similar to those of the study conducted by Rağbetli et al [33]. We observed a steady increase in *Staphylococcus aureus* resistance to aminopenicillins between 2016 and 2020, with a peak in 2020. Amoxicillin and amoxicillin/clavulanic acid showed full resistance to *Staphylococcus aureus* (100%). This result is quite similar to that of Andrianarivelo et al. in Madagascar [34].

*Staphylococcus aureus* was fully resistant (100%) in 2019 and less resistant (0%) to
ceftiraxone in 2020. This could be explained by the fact that the number of samples that were tested for ceftiraxone in 2020 was lower than those tested in previous years.

In 2020, *Staphylococcus aureus* were resistant to levofloxacin and aminoglycosides at 100% and 0% respectively. This could be explained by the routine empirical prescription of oral forms of quinolones by practitioners for urinary tract and soft tissue infections. Whereas aminoglycosides are mainly found in intravenous solutions and usually require hospitalizations to be administered to patients.

Andrianarivelo et al. noted in their study a 75% resistance rate to tetracyclines, which is different from our study 30% (in 2020). This is probably due to the fact that their paper focused only on *Staphylococcus aureus*, whereas we had a variety of species in this study. Secondly, tetracyclines are not commonly prescribed on a daily basis in our context.

Despite an apparent steady but gradual increase in *Staphylococcus aureus* resistance to the drug classes, namely aminopenicillins, cephalosporins and aminoglycosides in this study in 2020, this does not reflect the resistance of individual drugs by class.

We noted that *E. coli* resistance to penicillins, cephalosporins, quinolones and aminoglycosides increased over the years. These resistances almost doubled between 2016 and 2020; this has been reported in other studies by Saravanan and al, in Pondicherry and Ebongue and al, in Douala [24,31]. In 2020, there was 100% resistance to amoxicillin, ampicillin, oxacillin, cefotaxime, ciprofloxacin and ofloxacin. During the study period 2018 - 2020, cefotaxime had an optimal resistance of 100%. This could be explained by the fact that most of our samples proven from the paediatric ward and that cefotaxime is routinely combined with other antibiotics in the treatment of neonatal infections in our setting.

Piperacillin + tazobactam and carbapenems had a higher sensitivity 0% (less resistant) between 2019 - 2020 respectively. This is probably due to the fact that these drug classes are not commonly prescribed by health practitioners.

In 2020, *Klebsiella pneumonia* showed resistance to penicillins in general (85%). This is because, according to the literature, *K. pneumoniae* is naturally resistant to penicillins, especially amoxicillin and ticarcillin. We also noted a resistance to cephalosporins (54%), quinolones (17%) and aminoglycosides (19%). These results are similar to those of a study by Saravanan and al [31]. A study conducted in Cameroon reported less effective resistance of *K. pneumoniae* to Aminopenicillins [35].

Nevertheless, despite the recorded resistance of *Klebsiella pneumoniae* to Penicillins between 2016 and 2020, an overall increase in susceptibility of Penicillins, Cephalosporins, Quinolones and Aminoglycosides to *Klebsiella pneumoniae* was observed over the years in this study. We can observe from the 2020 data an excellent susceptibility of Tetracycline and Gentamycin to *Klebsiella pneumonia*, probably due to fewer prescriptions by physicians, but also due to the lack of routine resistance testing of *Klebsiella* species with these drug classes.

5. LIMITATION OF THE STUDY

The study did not determine if the resistance showed by the study was due to hospital-acquired or community acquired infection.

The study is retrospective and all the biological fluids were not included, so could not explain the trends of the bacteria concerning antibiotics.

6. CONCLUSION

This study aimed to determine the evolution of the antibiotic resistance profile of bacteria from January 2016 to June 2021 in the laboratory of the Yaounde University Teaching Hospital. The most represented department was the paediatric department and the most represented age group was 0-5 years. The most represented pathological product was blood. The most commonly identified strains were *coagulase negative staphylococci, Escherichia coli, Staphylococcus aureus* and *Klebsiella pneumoniae*. The evolution of *Escherichia coli* resistance to penicillin, aminoglycosides, quinolones and cephalosporins increased between 2016 and 2020. For *Staphylococcus aureus*, the evolution was increased between 2016 and 2020 for penicillin, constant for quinolones and reduced for cephalosporins, macrolides, tetracyclines and aminosides. For the *klebsiella Pneumoniae* strain, resistance was reduced for penicillins, cephalosporins and quinolones, but high for aminoglycosides. The magnitude of the challenge of antibiotic resistance in the medical world demonstrates the
urgency to act. It is important through multi-sectoral coordination that each sector, namely human, animal and environmental health, strengthens the surveillance of antibiotic resistance and raises awareness among both health professionals and the general population on the proper use and management of antibiotics and even antimicrobials in general.

ETHICAL APPROVAL

All authors hereby declare that the study has been approved by an Institutional Ethical Review Board (IERB) of the Faculty of Medicine and Biomedical Sciences. The approval number is N° 121/UYI/FMSB/VDRC/DAASR/CSD.

ACKNOWLEDGEMENTS

We would like to thanks the staffs of the YUTH’s laboratory unit for helping us during data collection and make our work more fluid.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Johnson AP. Surveillance of antibiotic resistance. Philos Trans R Soc Lond B Biol Sci. 2015;370:20140080.
2. Labi AK, Obeng-Nkrumah N, Narrey ET, Bjerrum S, Adu-Arriey NA, Ofori-Adjei YA, et al. Antibiotic use in a tertiary healthcare facility in Ghana: a point prevalence survey. Antimicrob Resist Infect Control. 2018;7:15.
3. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, et al. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17:616.
4. Bogale AA, Amhare AF, Chang J, Bogale HA, Betaw ST, Gebrehiwot NT, et al. Knowledge, attitude, and practice of self-medication with antibiotics among community residents in Addis Ababa, Ethiopia. Expert Rev Anti Infect Ther. 2019;17:459–66.
5. Adesida SA, Ezenta CC, Adagbada AO, Aladesokan AA, Coker AO. Carriage of multidrug resistant enterococcus faecium and enterococcus faecalis among apparently healthy humans. Afr J Infect Dis. 2017;11:83–9.
6. Costa T, Linhares I, Ferreira R, Neves J, Almeida A. Frequency and antibiotic resistance of bacteria implicated in community urinary tract infections in north aveiro between 2011 and 2014. Microb Drug Resist Larchmt N. 2018;24:493–504.
7. Mijović G, Čizmović L, Vuković MN, Stamatović S, Lopić M. Antibiotic consumption in hospitals and resistance rate of klebsiella pneumoniae and escherichia coli in montenegro. Acta Clin Croat. 2020;59:469–79.
8. Nagelkerke MMB, Sikwewa K, Makowa D, de Vries I, Chisi S, Dorigo-Zetsma JW. Prevalence of antimicrobial drug resistant bacteria carried by in- and outpatients attending a secondary care hospital in Zambia. BMC Res Notes. 2017;10:378.
9. Ingelbeen B, Koirala KD, Verdonck K, Barbé B, Mukendi D, Thong P, et al. Antibiotic use prior to seeking medical care in patients with persistent fever: a cross-sectional study in four low- and middle-income countries. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis; 2020.
10. Wall S. Prevention of antibiotic resistance - An epidemiological scoping review to identify research categories and knowledge gaps. Glob Health Action. 2019;12:1756191.
11. Amaha ND, Weldemariam DG, Abdu N, Tesfamariam EH. Prescribing practices using WHO prescribing indicators and factors associated with antibiotic prescribing in six community pharmacies in Asmara, Eritrea: a cross-sectional study. Antimicrob Resist Infect Control. 2019;8:163.
12. Home. AMR Review n.d. Accessed 18 July, 2021. Available:https://amr-review.org
13. GLASS. Global Antimicrobial Resistance Surveillance System (GLASS). WHO n.d. Accessed 11 February, 2021. Available:http://www.who.int/glass/en
14. Organization WH, Nations F and AO of the U, Health WO for A. Monitoring and evaluation of the global action plan on antimicrobial resistance: framework and recommended indicators. World Health Organization; 2019.
15. Elton L, Thomason MJ, Tembo J, Velavan TP, Pallerla SR, Arruda LB, et al. Antimicrobial resistance preparedness in sub-Saharan African countries. Antimicrob Resist Infect Control. 2020;9:145.

16. Chiorio A, Coll-Seck AM, Høie B, Moeloek N, Motsoaledi A, Rajatanavin R, et al. Antimicrobial resistance: A priority for global health action. Bull World Health Organ. 2015;93:439.

17. Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with extended-spectrum beta-lactamase-producing enterobacteriaceae and risk factors among healthy individuals: A systematic review and metaanalysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63:310–8.

18. ten Hove R-J, Tesfaye M, ten Hove WF, Nigussie M. Profiling of antibiotic resistance of bacterial species recovered from routine clinical isolates in Ethiopia. Ann Clin Microbiol Antimicrob. 2017;16:46.

19. kalambry A, Gaudré N, Drame BS, Poudiougo A, Kassogué A, Koné H, et al. Profil de résistance aux bêta-lactamines des entérobactéries isolées des prélèvements urinaires à l’Hôpital du Mali. Rev Malienne Infect Microbiol. French. 2019;14:6–13.

20. Feldman C, Anderson R. Antibiotic resistance of pathogens causing community-acquired pneumonia. Semin Respir Crit Care Med. 2012;33:232–43.

21. Ashley EA, Lubell Y, White NJ, Turner P. Antimicrobial susceptibility of bacterial isolates from community acquired infections in Sub-Saharan Africa and Asian low and middle income countries. Trop Med Int Health TM IH. 2011;16:1167–79.

22. Hanif E, Hassan SA. Evaluation of antibiotic resistance pattern in clinical isolates of Staphylococcus aureus. Pak J Pharm Sci. 2019;32:1749–53.

23. Lonchel CM, Meex C, Gangoué-Pléboji J, Boreux R, Assoumou M-CO, Melin P, et al. Proportion of extended-spectrum β-lactamase-producing Enterobacteriaceae in community setting in Ngaoundere, Cameroon. BMC Infect Dis. 2012;12:1–7.

24. Ebongue CO, Tsiazok MD, Mefo’o JPN, Ngaba GP, Beyïha G, Adiogo D. Evolution of antibiotic resistance of Enterobacteriaceae isolated at the Douala General Hospital from 2005 to 2012. Pan Afr Med J. 2015;20:227.

25. Ebongue CO, Mefo’o JN, Dongho EN, Moukoko EE, Adiogo D, Beyïhab G. Profil Bactériologique et sensibilité aux antibiotiques des isolats d’hémoculture (2006 – 2011) à Douala, Cameroun. Rev Malienne D’Infectiologie Microbiol. French.2014;27–39.

26. Noeske J, Yakam AN, Foe JLA, Nguafack D, Kuaban C. Rifampicin resistance in new bacteriologically confirmed pulmonary tuberculosis patients in Cameroon: A cross-sectional survey. BMC Res Notes. 2018;11:580.

27. Détermination de la sensibilité aux antibiotiques. In : CASFM/EUCAST : Société Française de Microbiologie Ed. 2020;6–25.

28. Cheesbrough M. Microbiological tests. Dist. Lab. Pract. Trop. Ctries., vol. 2, New York: Cambridge University Press. 2006;1–266.

29. Alemayehu T, Ali M, Mitiku E, Hailemariam M. The burden of antimicrobial resistance at tertiary care hospital, southern Ethiopia: a three years’ retrospective study. BMC Infect Dis. 2019;19:585.

30. Metchim A, Madouni Z. Surveillance de la résistance aux antibiotiques chez les bactéries sentinelles en milieu communautaire. French; 2017.

31. Saravanan R, Raveendaran V. Antimicrobial resistance pattern in a tertiary care hospital: An observational study. J Basic Clin Pharm. 2013;4:56–63.

32. Black CG, Tavares L, Stachel A, Ratner AJ, Randis TM. Distribution of late-onset neonatal sepsis pathogens differs in inpatient and outpatient settings. Am J Perinatol 2019;36:1136–41.

33. Rağbetli C, Parlak M, Bayram Y, Guducuoglu H, Ceylan N. Evaluation of antimicrobial resistance in staphylococcus aureus isolates by years. Interdiscip Perspect Infect Dis 2016;2016:9171395.

34. Andrianarivelo AM, Andriamandimbisoa TH, Rakotondraoeina LM, Ratsimbazafy ABA, Razafimanantsoa FE, Raharisoa AA, et al. Status of resistance to antimicrobial agents of Staphylococcus aureus strains at the laboratory of microbiology of the HU-JRA Antananarivo. Afr J Clin Exp Microbiol. 2017;18:133–8.
35. Nzalie RN-T, Gonsu HK, Koulla-Shiro S. Bacterial etiology and antibiotic resistance profile of community-acquired urinary tract infections in a Cameroonian City. Int J Microbiol. 2016;2016:3240268.

© 2021 Yopa et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle4.com/review-history/74753